Connect Biopharma Holdings Ltd.(CNTB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNTB Connect Biopharma Holdings Ltd.

Market Closed 12-26 16:00:00 EST

2.69

-0.04

-1.47%

盘后2.69

+0.000.00%

19:55 EST

High2.89	Low2.65	Vol60.47K
Open2.75	D1 Closing2.73	Amplitude8.79%
Mkt Cap150.38M	Tradable Cap38.59M	Total Shares55.90M
T/O165.18K	T/O Rate0.42%	Tradable Shares14.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNTB","market":"US","secType":"STK","nameCN":"Connect Biopharma Holdings Ltd.","latestPrice":2.69,"timestamp":1766782800000,"preClose":2.73,"halted":0,"volume":60472,"hourTrading":{"tag":"盘后","latestPrice":2.69,"preClose":2.69,"latestTime":"19:55 EST","volume":1002,"amount":2695.38,"timestamp":1766796903154},"delay":0,"floatShares":14344108,"shares":55903513,"eps":-0.888362,"marketStatus":"Market Closed","change":-0.04,"latestTime":"12-26 16:00:00 EST","open":2.75,"high":2.89,"low":2.65,"amount":165184.0090048,"amplitude":0.087912,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.888362,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766998800000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1616126400000,"exchange":"NASDAQ","adjPreClose":2.73,"preHourTrading":{"tag":"盘前","latestPrice":2.8,"preClose":2.73,"latestTime":"09:04 EST","volume":376,"amount":1080.0999688000002,"timestamp":1766757880262},"postHourTrading":{"tag":"盘后","latestPrice":2.69,"preClose":2.69,"latestTime":"19:55 EST","volume":1002,"amount":2695.38,"timestamp":1766796903154},"volumeRatio":0.36448896710690004,"impliedVol":2.2243,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/CNTB","defaultTab":"news","newsList":[{"id":"2593544341","title":"Connect Biopharma Board Member Kan Chen Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2593544341","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593544341?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:32","pubTimestamp":1766525550,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings Ltd. announced that Kan Chen, Ph.D., a partner at Qiming Venture Partners, has resigned from its Board of Directors and the Nominating and Corporate Governance Committee, effective immediately. The resignation follows the company's recent shift to a more U.S.-centric strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL47CRmf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2588277472","title":"Connect Biopharma Initiated at Buy by Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2588277472","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588277472?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:10","pubTimestamp":1764609000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 12:10 ET (17:10 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2585605524","title":"Connect Biopharma Holdings to Present at Evercore Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585605524","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585605524?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:00","pubTimestamp":1763992816,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings Ltd. will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:50 a.m. ET. The live webcast of the presentation will be accessible through the Investors section of the company's website, with an archived replay available for approximately 90 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL7ZYTkQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","NDAQ","LU2095319765.USD","LU2210149790.SGD","CNTB","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2584009946","title":"Connect Biopharma Reports Significant Loss Amid Development Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2584009946","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584009946?lang=en_us&edition=fundamental","pubTime":"2025-11-18 12:07","pubTimestamp":1763438837,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings Ltd. ( ($CNTB) ) has released its Q3 earnings. Here is a breakdown of the information Connect Biopharma Holdings Ltd. pr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/connect-biopharma-reports-significant-loss-amid-development-efforts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/connect-biopharma-reports-significant-loss-amid-development-efforts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2583563117","title":"Connect Biopharma Price Target Maintained With a $10.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2583563117","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583563117?lang=en_us&edition=fundamental","pubTime":"2025-11-13 18:05","pubTimestamp":1763028300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 05:05 ET (10:05 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2582372179","title":"Connect Biopharma Hldgs Q3 EPS $(0.31) Misses $(0.27) Estimate, Sales $16.000K Down From $1.219M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2582372179","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582372179?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:07","pubTimestamp":1762956441,"startTime":"0","endTime":"0","summary":"Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.27) by 14.81 percent. This is a 34.78 percent decrease over losses of $(0.23) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48802758/connect-biopharma-hldgs-q3-eps-0-31-misses-0-27-estimate-sales-16-000k-down-from-1-219m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2582372601","title":"Connect Biopharma Reports Q3 2025 Results and Advances Rademikibart Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2582372601","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582372601?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:03","pubTimestamp":1762956205,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings Ltd. reported financial results for the third quarter of 2025 and provided a business update. The company announced ongoing recruitment for its Phase 2 Seabreeze STAT studies evaluating rademikibart in acute exacerbations of asthma and chronic obstructive pulmonary disease , with topline data expected in the first half of 2026. In China, Simcere, Connect Biopharma's exclusive licensee, submitted a New Drug Application for rademikibart for the treatment of atopic dermatitis, which was accepted by the National Medical Products Administration in July 2025. The company also presented positive data at ERS 2025 highlighting the potential of rademikibart in patients with a range of type 2 inflammatory markers. Connect Biopharma completed the termination of its American Depositary Receipt program and directly listed its ordinary shares on the Nasdaq Global Market under the symbol \"CNTB\". As of September 30, 2025, cash, cash equivalents, and short-term investments tot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL1Tys0f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2582372591","title":"Connect Biopharma reports third quarter 2025 financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582372591","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582372591?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:00","pubTimestamp":1762956018,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings Ltd. reported a net loss of $17.2 million, or $0.31 per share, for the third quarter of 2025, compared to a net loss of $12.9 million, or $0.23 per share, for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $40.4 million, or $0.73 per share, compared to $6.7 million, or $0.12 per share, for the same period in 2024. Cash, cash equivalents and short-term investments totaled $54.8 million as of September 30, 2025, with the company expecting these funds to support operations into 2027. Key business developments included the ongoing recruitment for Phase 2 Seabreeze STAT studies in asthma and COPD, the acceptance of a New Drug Application for rademikibart in atopic dermatitis by China's NMPA, and the termination of the American Depositary Receipt program, with ordinary shares now directly listed on Nasdaq.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL5pJJpF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","BK4585","CNTB","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4588","BK4139","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2582631372","title":"Press Release: Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582631372","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582631372?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:00","pubTimestamp":1762956000,"startTime":"0","endTime":"0","summary":"-- Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 --. -- New Drug Application for rademikibart for the treatment of atopic dermatitis submitted by Simcere, the Company's exclusive licensee in Greater China, was accepted by China's NMPA --. -- Completed termination of American Depositary Receipt program and directly listed our ordinary shares on Nasdaq --. -- Presented positive data at ERS 2025 supporting the potential of rademikibart to deliver differentiated efficacy and safety in patients across a broad range of baseline type 2 inflammatory markers --. SAN DIEGO, Nov. 12, 2025  -- Connect Biopharma Holdings Limited  , a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and nine months ended September 30, 2025, and provided a business update.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EOS","BK4132","AD","CNTB"],"gpt_icon":0},{"id":"2579461353","title":"Connect Biopharma Holdings Ltd : Btig Initiates Coverage With Buy Rating; Price Target $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2579461353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579461353?lang=en_us&edition=fundamental","pubTime":"2025-10-31 20:20","pubTimestamp":1761913213,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC2Z8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2579571614","title":"Connect Biopharma Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2579571614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579571614?lang=en_us&edition=fundamental","pubTime":"2025-10-31 18:26","pubTimestamp":1761906360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2025 06:26 ET (10:26 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2579457314","title":"Connect Biopharma initiated with a Buy at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2579457314","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579457314?lang=en_us&edition=fundamental","pubTime":"2025-10-31 18:10","pubTimestamp":1761905432,"startTime":"0","endTime":"0","summary":"BTIG initiated coverage of Connect Biopharma (CNTB) with a Buy rating and $10 price target The firm believes rademikibart is “set up to thrive” in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/connect-biopharma-initiated-with-a-buy-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/connect-biopharma-initiated-with-a-buy-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2571635390","title":"Buy Rating for Connect Biopharma: Promising Clinical Data and Market Potential for Rademikibart","url":"https://stock-news.laohu8.com/highlight/detail?id=2571635390","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571635390?lang=en_us&edition=fundamental","pubTime":"2025-09-29 23:55","pubTimestamp":1759161354,"startTime":"0","endTime":"0","summary":"Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Connect Biopharma Holdings and keeping the price target at $7.00. Brandon Fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-connect-biopharma-promising-clinical-data-and-market-potential-for-rademikibart-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-connect-biopharma-promising-clinical-data-and-market-potential-for-rademikibart-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2571339711","title":"Connect Biopharma presents data on rademikibart at ERS Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2571339711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571339711?lang=en_us&edition=fundamental","pubTime":"2025-09-29 21:21","pubTimestamp":1759152077,"startTime":"0","endTime":"0","summary":"Connect Biopharma (CNTB) Holdings presented data supporting rademikibart, the Company’s investigational, next-generation, potentially best-in-class...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/connect-biopharma-presents-data-on-rademikibart-at-ers-congress-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/connect-biopharma-presents-data-on-rademikibart-at-ers-congress-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2571336758","title":"Connect Biopharma Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2571336758","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571336758?lang=en_us&edition=fundamental","pubTime":"2025-09-29 21:00","pubTimestamp":1759150841,"startTime":"0","endTime":"0","summary":"Connect Biopharma Announces Promising Phase 2 Data for Rademikibart in Asthma and COPD, with Topline Results Expected in 1H 2026. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire  on September 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDLhnd0Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","BK4585","IE00BKPKM429.USD","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","NDAQ","CNTB","LU2095319765.USD","BK4139"],"gpt_icon":0},{"id":"2567483693","title":"Connect Biopharma Executives Increase Share Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2567483693","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567483693?lang=en_us&edition=fundamental","pubTime":"2025-09-16 21:26","pubTimestamp":1758029202,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings ( ($CNTB) ) has issued an announcement. Between September 2024 and September 2025, Barry D. Quart, CEO and Director of C...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/connect-biopharma-executives-increase-share-holdings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/connect-biopharma-executives-increase-share-holdings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2564949543","title":"BRIEF-Connect Biopharma Completes Termination Of Its American Depositary Receipt Program And Directly Lists Its Ordinary Shares On Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2564949543","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564949543?lang=en_us&edition=fundamental","pubTime":"2025-09-03 22:33","pubTimestamp":1756910017,"startTime":"0","endTime":"0","summary":"BRIEF-Connect Biopharma Completes Termination Of Its American Depositary Receipt Program And Directly Lists Its Ordinary Shares On NasdaqConnect Biopharma Holdings Ltd CNTB.O:CONNECT BIOPHARMA COMPLET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nFWN3UQ0HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"gpt_icon":0},{"id":"2564339566","title":"Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2564339566","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564339566?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:40","pubTimestamp":1756903217,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha  treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL4TYCX0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2564938183","title":"Connect Biopharma Completes Termination of Its American Depositary Receipt Program and Directly Lists Its Ordinary Shares on Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2564938183","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564938183?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:08","pubTimestamp":1756901314,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nFWN3UQ0HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTB","BK4139"],"gpt_icon":0},{"id":"2564398475","title":"Connect Biopharma Holdings Ltd. Transitions to Direct Nasdaq Listing, Enhancing U.S. Market Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398475?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:00","pubTimestamp":1756900817,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings Ltd. has transitioned from an American Depositary Receipt  program to directly listing its ordinary shares on the Nasdaq Global Market. As of September 3, 2025, the company's ordinary shares began trading on Nasdaq under the symbol \"CNTB\". The ADRs were exchanged for ordinary shares at a one-for-one ratio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire  on September 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL7NK2yX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","LU0314104364.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU2095319765.USD","BK4585","IE00BKPKM429.USD","BK4112","CNTB","BK4588","IE00B64PRP62.GBP","NDAQ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.connectbiopharm.com","stockEarnings":[{"period":"1week","weight":0.185},{"period":"1month","weight":-0.0495},{"period":"3month","weight":0.7025},{"period":"6month","weight":1.69},{"period":"1year","weight":1.7732},{"period":"ytd","weight":0.9493}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0156},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1226},{"period":"1year","weight":0.148},{"period":"ytd","weight":0.1778}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.001613},{"month":2,"riseRate":0.5,"avgChangeRate":-0.038597},{"month":3,"riseRate":0.25,"avgChangeRate":-0.093859},{"month":4,"riseRate":0.4,"avgChangeRate":-0.018116},{"month":5,"riseRate":0.6,"avgChangeRate":-0.072705},{"month":6,"riseRate":0.8,"avgChangeRate":0.091691},{"month":7,"riseRate":0.4,"avgChangeRate":0.150673},{"month":8,"riseRate":0.8,"avgChangeRate":0.204473},{"month":9,"riseRate":0.2,"avgChangeRate":-0.084295},{"month":10,"riseRate":0.4,"avgChangeRate":0.007717},{"month":11,"riseRate":0.2,"avgChangeRate":-0.108453},{"month":12,"riseRate":0.8,"avgChangeRate":0.133129}],"exchange":"NASDAQ","name":"Connect Biopharma Holdings Ltd.","nameEN":"Connect Biopharma Holdings Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Connect Biopharma Holdings Ltd.(CNTB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Connect Biopharma Holdings Ltd.(CNTB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Connect Biopharma Holdings Ltd.,CNTB,Connect Biopharma Holdings Ltd.股票,Connect Biopharma Holdings Ltd.股票老虎,Connect Biopharma Holdings Ltd.股票老虎国际,Connect Biopharma Holdings Ltd.行情,Connect Biopharma Holdings Ltd.股票行情,Connect Biopharma Holdings Ltd.股价,Connect Biopharma Holdings Ltd.股市,Connect Biopharma Holdings Ltd.股票价格,Connect Biopharma Holdings Ltd.股票交易,Connect Biopharma Holdings Ltd.股票购买,Connect Biopharma Holdings Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Connect Biopharma Holdings Ltd.(CNTB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Connect Biopharma Holdings Ltd.(CNTB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction